Boiron : Q2 2021 sales: a redeeming base effect – Operating losses can be expected at end-June – Visibility still middling
>Q2: +1.8% - Q2 sales came in at € 98.3m, i.e. 1.8%. In H1, sales were down 25% to € 189.9m (-23% at cc), with stronger consolidation (-42% and -38% at cc) in North America which had a good H1 2020.In this context, the group still anticipates a significant decline in sales and underlying operating profit.New products (essentially in France, Italy and Spain for the time being): Mag’Nuit®, Osmobiotic®, Cocyntal®, plant extracts, Dermoplasmine®, new homeotherap...Boiron manufactures and markets homeopathic medicines. Homeopathic medicines are prepared from vegetable, animal, mineral, or chemical substances, which are diluted. Co. sells three types of products in 59 countries: Non-proprietary homeopathic medicines, OTC family medication specialties, and Other products. There are two large families of homeopathic medicines: Those associated with precise therapeutic indications and dosage, and those that do not mention a therapeutic indication or dosage. Co. supports homeopathy education and training organizations for healthcare professionals. Some of Co.'s brand names include Oscillococcinum®, Stodal®, S?datif PC®, and Coryzalia.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.